A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs APS 001F (Primary) ; Flucytosine; Maltose
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Anaeropharma Science
- 16 Feb 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018.
- 16 Feb 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.
- 29 Dec 2014 Planned End Date changed from 1 Sep 2015 to 1 Aug 2016, as reported by ClinicalTrials.gov.